Overview

A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years

Status:
Not yet recruiting

Trial end date:
2025-01-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and effectiveness of treatment with once daily (QD) oral administration of dexlansoprazole capsules (15, 30, and 60 mg) in pediatric participants aged 1 to 11 years with symptomatic nonerosive gastroesophageal reflux disease (GERD).

Phase:

Phase 2

Details

Lead Sponsor:

Takeda

Treatments:

Dexlansoprazole
Lansoprazole